This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ratain MJ et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505–2512
Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434
Motzer RJ et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16–24
Motzer RJ et al. (2006) Phase 3 randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma [abstract #LBA3]. Proc Am Soc Clin Oncol 24: s2
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Srinivasan, R., Linehan, W. Antiangiogenic therapy in renal cell carcinoma: from concept to reality. Nat Rev Urol 4, 74–75 (2007). https://doi.org/10.1038/ncpuro0705
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro0705